New weight drug HU6 tested in early human study
NCT ID NCT07170189
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new drug called HU6 in 59 overweight adults. The goal was to see how safe the drug is and how the body processes it in tablet and capsule forms. Participants took different doses, and researchers measured drug levels in the blood. This study does not test weight loss directly, but gathers important safety information for future research.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nucleus Network
Minneapolis, Minnesota, 55114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug combo tip the scales against obesity?
- Does when you eat carbs and protein reshape blood sugar control?
- Can a weekly shot keep metabolism from slowing after weight loss?
- Can Early-Life factors steer preterm and term infant health?
- Can a new injection help tackle obesity? a trial investigates
- Can a new injection help shed pounds? a trial investigates